Clinical Trial: A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07876076) titled 'A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response' on Oct. 02.

Brief Summary: This is a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ADX-001 in healthy adult participants

Study Start Date: Oct. 06

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: ADX-001

ADX-001 administered as a single dose according to assigned cohort: 150 mg SC, 300 mg SC, 600 mg SC,...